CCT129957 is a novel and potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of about 3 μM and a GC50 of 15 μM.CCT129957 exhibits anticancer activity and inhibits Ca2+ release in squamous cells.

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:50 mg/mL (161.64 mM)

PLC-γ:3 μM

The left phenyl group is situated within a hydrophobic pocket formed by various amino acids. The predicted binding mode of CCT129957 exhibits a robust hydrogen bonding pattern and hydrophobic contacts[1].CCT129957 inhibits the growth of renal UO-31 and breast T-47D cancer cells by approximately 60-70%[2].